Aratana Therapeutics

Aratana Therapeutics is a pioneer in pet therapeutics focused on licensing, developing and commercializing innovative therapeutics for dogs and cats. Its goal is to provide veterinarians and pet owners with new therapeutics that are driven by science and specifically made for pets. The Сompany's pipeline includes therapeutic candidates for the potential treatment of pain, inappetence, viral diseases, allergy, cancer and other serious medical conditions. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets.


TypeSubsidiary
Parent CompanyElanco
HQLeawood, KS, US
Founded2010
Websitearatana.com
Cybersecurity ratingAMore
Aratana Therapeutics was founded in 2010 and is headquartered in Leawood, KS, US

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Aratana Therapeutics

Ernst Heinen

Ernst Heinen

Chief Development Officer
Craig Tooman

Craig Tooman

President, Chief Executive Officer and Board Director
Chris Ready

Chris Ready

Vice President of Sales and Marketing
Rhonda Hellums

Rhonda Hellums

Chief Financial Officer and Treasurer
Show more

Aratana Therapeutics Office Locations

Aratana Therapeutics has offices in Leawood, San Diego and Leuven
Leawood, KS, US (HQ)
11400 Tomahawk Creek Pkwy #340
San Diego, CA, US
10451 Roselle St #200a
Leuven, BE
1 Ambachtenlaan
Show all (3)

Aratana Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2010

Total Funding

$76.8 m

Investors

Aratana Therapeutics is a subsidiary of Elanco

Aratana Therapeutics Revenue

Embed Graph
View revenue for all periods
Aratana Therapeutics's revenue was reported to be $35.41 m in FY, 2018
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

123.0k767.0k678.0k38.6m25.6m35.4m

Revenue growth, %

524%(12%)5586%

Cost of goods sold

108.0k333.0k365.0k3.1m16.4m6.8m

Gross profit

15.0k434.0k313.0k35.4m9.2m28.6m
Quarterly
USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Revenue

176.0k300.0k43.0k156.0k230.0k229.0k172.0k38.0m40.0k3.8m5.2m6.2m4.0m4.9m21.6m7.4m

Cost of goods sold

110.0k109.0k138.0k19.0k1.7m286.0k3.1m3.7m3.7m536.0k1.3m2.2m1.5m

Gross profit

46.0k121.0k91.0k153.0k36.3m(246.0k)701.0k1.5m2.5m3.5m3.6m19.4m5.8m

Gross profit Margin, %

29%53%40%89%95%(615%)18%28%40%87%73%90%79%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

41.1m9.8m26.8m87.3m66.9m41.4m

Accounts Receivable

352.0k60.0k87.0k2.4m2.2m

Prepaid Expenses

274.0k900.0k1.5m1.6m1.8m

Inventories

55.0k427.0k1.3m11.1m13.6m11.4m
USDQ2, 2013

Debt/Equity

-0.1 x

Debt/Assets

0.1 x

Financial Leverage

-0.8 x
Show all financial metrics

Aratana Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

Aratana Therapeutics Online and Social Media Presence

Embed Graph

Aratana Therapeutics News and Updates

Aratana Therapeutics Reports Voting Results from 2019 Annual Meeting of Stockholders

LEAWOOD, Kan., June 7, 2019 /PRNewswire/ -- Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, today announced the voting results for the four proposals considered and voted...

Thinking about buying stock in Aurora Cannabis, The Walt Disney Co., Aratana Therapeutics, Regional Health Properties, or Spotify?

NEW YORK, April 29, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, DIS, PETX, RHE, and SPOT. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Aratana Therapeutics, Inc.

NEW YORK, April 26, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Aratana Therapeutics, Inc. (NASDAQ: PETX) and its board of directors for breach of fiduciary duty concerning the proposed acquisition of the company by Elanco Animal Health Incorporated...

Animal health giant Elanco to acquire Aratana Therapeutics

Shares of Aratana Therapeutics shot up 39% in premarket trade on Friday after Elanco Animal Health announced it would be acquiring the pet therapeutics company in a deal worth up to $245 million. For each share of Aratana, shareholders will receive 0.1481 shares of Elanco stock and one contingent …

Aratana Therapeutics to be Acquired by Elanco Animal Health

LEAWOOD, Kan., April 26, 2019 /PRNewswire/ -- Aratana Therapeutics (NASDAQ: PETX), a pet therapeutics company focused on developing and commercializing innovative therapeutics for dogs and cats, announced it has signed an agreement to be acquired by Elanco Animal Health (NYSE: ELAN), its...

Aratana Therapeutics to Report First Quarter 2019 Financial Results

LEAWOOD, Kan., April 22, 2019 /PRNewswire/ -- Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, will host a live conference call on Wednesday, May 8 at 4:30 p.m. ET to...
Show more

Aratana Therapeutics Blogs

Aratana Therapeutics’ Stockholders Adopt Merger Agreement with Elanco Animal Health

The Company reported 72% of the Company’s common stock outstanding as of the July 14, 2019 record date adopted the merger agreement and approximately 73% of the Company’s outstanding common stock as of the June 14, 2019 record date was present in person or represented by proxy at the Special Meeting…

Aratana Therapeutics Granted FDA Approval of NOCITA® (bupivacaine liposome injectable suspension) 10 mL Vial

The U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM) approved an additional vial size (10 mL) for NOCITA® (bupivacaine liposome injectable suspension). NOCITA is currently available in a 20 mL vial size and Aratana continues to anticipate commercial availability of the NOCITA…

Aratana Therapeutics Reports First Quarter 2019 Financial Results

The Company announced its first quarter 2019 financial results and recent business highlights. The post Aratana Therapeutics Reports First Quarter 2019 Financial Results appeared first on Aratana Therapeutics.

Aratana Therapeutics to Present at Stifel 2019 Dental & Veterinary Conference

The Company plans on presenting at the Stifel Dental & Veterinary Conference on Wednesday, May 29, 2019 at 8:00 a.m. ET in New York City. The post Aratana Therapeutics to Present at Stifel 2019 Dental & Veterinary Conference appeared first on Aratana Therapeutics.

Aratana Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results

The Company will host a live conference call on Tuesday, March 12, 2019 at 4:30 p.m. ET to discuss financial results from the fourth quarter and full year ended December 31, 2018. The post Aratana Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results appeared first on Aratana Th…

Aratana Therapeutics’ Board of Directors Appoints Craig Tooman Chief Executive Officer

The Company announced today the Company’s Board of Directors has appointed Craig Tooman to serve as President and Chief Executive Officer of Aratana, and elected Tooman to the Board of Directors. The post Aratana Therapeutics’ Board of Directors Appoints Craig Tooman Chief Executive Officer appeared…
Show more

Aratana Therapeutics Frequently Asked Questions

  • When was Aratana Therapeutics founded?

    Aratana Therapeutics was founded in 2010.

  • Who are Aratana Therapeutics key executives?

    Aratana Therapeutics's key executives are Ernst Heinen, Craig Tooman and Chris Ready.

  • How many employees does Aratana Therapeutics have?

    Aratana Therapeutics has 79 employees.

  • What is Aratana Therapeutics revenue?

    Latest Aratana Therapeutics annual revenue is $35.4 m.

  • What is Aratana Therapeutics revenue per employee?

    Latest Aratana Therapeutics revenue per employee is $448.3 k.

  • Who are Aratana Therapeutics competitors?

    Competitors of Aratana Therapeutics include Bimeda, Admescope and Chalante.

  • Where is Aratana Therapeutics headquarters?

    Aratana Therapeutics headquarters is located at 11400 Tomahawk Creek Pkwy #340, Leawood.

  • Where are Aratana Therapeutics offices?

    Aratana Therapeutics has offices in Leawood, San Diego and Leuven.

  • How many offices does Aratana Therapeutics have?

    Aratana Therapeutics has 3 offices.